IDH2 and thyroid gland carcinoma: However, TERTp mutation may be a second genetic event following oncogenic activation, such as IDH mutation in diffuse gliomas, BRAF V600E mutation in thyroid cancer, and FGFR3 mutation in urothelial carcinoma29,31,32.